CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Catalyst settlement with Teva a positive event, says BofA
BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock was recently at $22.30, up 14%, and is up about 48% over the past 52 weeks.
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases,
US analysts list Israeli giants Teva, Wix in 2025 top picks
In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...
bovnews11h
Why Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Surpassing 15.12% from Its 50-Day SMA?
Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...
Investor's Business Daily on MSN1d
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.
Zacks.com on MSN16h
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
bovnews2d
Teva Pharmaceutical Industries Ltd (TEVA) Stock: Surpassing Expectations in the Market?
Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...
Yahoo23d
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study. Researchers Found A Link Between This Childhood Virus And ...
Duvakitug And Teva's Growth: A Game Changer In Pharma
Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...
globes.co.il1d
US analysts list Teva, Wix in 2025 top picks
Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...